Moderna Dropped by 20% This Week -- Is It a Smart Buy Right Now?

Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna (NASDAQ: MRNA). The company, which was a leader in developing one of the initial COVID-19 vaccines, has plunged by 20% for the week as of mid-day Thursday.The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin. The prior forecast called for $2.5 billion to $3.5 billion in sales for 2025, but the updated guidance calls for $1.5 billion to $2.5 billion. At the midpoint, that represents a $1 billion reduction, or 50% lower revenue. Moderna had previously said that it will be break even on operating cash flow by 2028, which had already been pushed back. Now investors aren't so sure.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool